Monia Casamenti, a 44-Year-old Supermarket Worker and Mother From Forlì
Monia Casamenti, a 44-year-old supermarket worker and mother from Forlì, launched an online fundraising campaign after discovering her pancreatic cancer diagnosis through an online health portal and finding herself blocked from accessing a new experimental American pill costing €40,000 per month, ForlìToday reported.
Diagnosis Discovered Through Online Health Portal
Casamenti discovered her pancreatic cancer diagnosis in early September by opening her electronic health record rather than receiving a phone call from medical staff, she told ForlìToday. She recalled experiencing severe stomach pain in August and initially receiving paracetamol at Forlì before visiting a Cesena hospital the following weekend with yellow eyes.
Biopsies revealed a bile blockage, but after administrative delays and a second round of testing, the cancer diagnosis appeared in her online health portal without prior verbal notice.
“Lunedì ho chiamato il reparto di gastroenterologia arrabbiata come un puma e dicendo che nessuno, durante il ricovero e i prelievi, aveva detto qualcosa, fatto delle ipotesi su una cosa del genere,” Casamenti told ForlìToday.
Gene Match Found but Illness Halted Trial Access
After contacting the Meldola Scientific Institute for the Study and Treatment of Tumors (IRST), Casamenti sought out specialist care in Verona and learned about daraxonrasib, an American pill that inhibits RAS proteins and can suppress tumor growth in specific gene matches. Testing confirmed she carried the target gene, but she fell ill the day before traveling to begin the therapy, closing the door on the trial. Hospitalized at IRST for standard chemotherapy, she turned to crowdfunding. With assistance from her husband, mother, and children aged 16 and 22, she opened a GoFundMe campaign under the name “mamma con tumore al pancreas cerca aiuto” to cover the treatment costs, ForlìToday reported. Meanwhile, regional and national discussions surrounding the drug have intensified. Undici organizzazioni impegnate nella tutela dei pazienti oncologici hanno sollecitato le autorità affinché forniscano accesso gratuito al daraxonrasib, in seguito alla sua autorizzazione europea.
Lombardy welfare councilor Guido Bertolaso announced regional readiness to act as a bridge between the Italian Medicines Agency (AIFA), the Ministry of Health, and manufacturer Revolution Medicines, following a special regional funding intervention for another metastatic patient named Jessica, according to Quotidiano Sanità.
“Il nostro impegno per Jessica deve diventare un’occasione per costruire, insieme alle istituzioni nazionali e alle associazioni, un percorso che offra le stesse opportunità agli altri pazienti nelle medesime condizioni cliniche,” Bertolaso said, as reported by Corriere della Sera.
Clinical data for daraxonrasib stems from the Phase 3 RASolute 302 trial involving 500 patients, published in the New England Journal of Medicine and presented at the 2026 American Society of Clinical Oncology congress, which demonstrated a doubling of median overall survival compared to standard chemotherapy, SKY reported.
An additional trial presentation in Barcelona involving 61 patients up to September 28, 2026, further highlighted extended disease control when combining the molecule with chemotherapy, according to Il Sole 24 ORE. AIFA announced on November 18, 2026, that it is conducting a progressive evaluation of clinical data to accelerate national procedures, while broader discussions regarding pricing, reimbursement, and an expanded access program remain pending.